Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer [PDF]
Frontiers in OncologyBackgroundColorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin-based chemotherapy is a cornerstone of treatment for many CRC patients; however, the development of chemoresistance severely limits its therapeutic ...
Xiaopeng Zhan +9 more
doaj +2 more sources
Efficacy of Nanofiber Sheets Incorporating Oxaliplatin in Gastrointestinal Cancer Xenograft Models [PDF]
NanomaterialsOxaliplatin is an anticancer drug used to treat colorectal and gastric cancers. In many cases, chemotherapy is discontinued due to adverse events caused by anticancer drugs. To address this challenge, we developed a sustained-release drug delivery system
Fusao Sumiyama +16 more
doaj +2 more sources
Oxaliplatin versus irinotecan as first-line therapy in metastatic colorectal cancer with prior adjuvant treatment: a retrospective study on efficacy, sequential therapy, and the impact of thrombocytopenia [PDF]
Frontiers in OncologyBackgroundThe comparative efficacy of oxaliplatin versus irinotecan as first-line therapy in mCRC patients with prior adjuvant treatment remains unclear.ObjectivesTo compare the efficacy of first-line oxaliplatin-based versus irinotecan-based ...
Han Shan +8 more
doaj +2 more sources
Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. [PDF]
PLoS ONE, 2015 The platinum-based anticancer drug oxaliplatin is important clinically in cancer treatment. However, the role of multidrug resistance-associated protein 2 (MRP2) in controlling oxaliplatin membrane transport, in vivo handling, toxicity and therapeutic ...
Khine Myint +3 more
doaj +3 more sources
Targeting FBXL5 to induce ferroptosis and reverse oxaliplatin resistance in iron-rich colorectal cancer [PDF]
Scientific ReportsOxaliplatin resistance remains a major challenge in colorectal cancer (CRC) treatment. We investigated the FBXL5/IREB2/TFRC axis in ferroptosis-mediated resistance reversal.
Miaomiao Wang +7 more
doaj +2 more sources
Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]
, 2013 Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
A Jemal +52 more
core +15 more sources
Frontiers in Oncology, 2022 BackgroundAddition of oxaliplatin to adjuvant 5-FU has significantly improved the disease-free survival and served as the first line adjuvant chemotherapy in advanced colorectal cancer (CRC) patients. However, a fraction of patients remains refractory to
Khamushavalli Geevimaan +18 more
doaj +1 more source
Frontiers in Molecular Neuroscience, 2021 Use of chemotherapy drug oxaliplatin is associated with painful peripheral neuropathy that is exacerbated by cold. Remodeling of ion channels including TRP channels in dorsal root ganglion (DRG) neurons contribute to the sensory hypersensitivity ...
Bin Wu +8 more
doaj +1 more source
Pharmaceuticals, 2022 Aberrant expression of genes contributes to the chemoresistance of colorectal cancer (CRC) treatment. This study aimed to identify genes associated with the chemoresistance of oxaliplatin-based chemotherapy in CRC patients and to construct a signature ...
Yixin Yin +5 more
doaj +1 more source
MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer
Frontiers in Oncology, 2021 Colorectal cancer is one of the most common malignancies worldwide. Oxaliplatin is the first-line chemotherapeutic agent for the treatment of advanced colorectal cancer. However, acquired resistance to oxaliplatin limits its therapeutic efficacy, and the
Xiao-Lan Qian +7 more
doaj +1 more source